---
layout: default
title: Tinidazole
parent: Model Prediction Only (L5)
nav_order: 830
evidence_level: L5
indication_count: 10
---

# Tinidazole
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Tinidazole: From Antiprotozoal/Antibacterial Therapy to Postmenopausal Atrophic Vaginitis

## One-Sentence Summary

Tinidazole is a 5-nitroimidazole antiprotozoal/antibacterial agent (per the evidence pack's own mechanistic notes, used against *Trichomonas vaginalis*, amoebiasis, and giardiasis); no formal original-indication or regulatory label text was provided in this dataset. The TxGNN model's top prediction is **Postmenopausal Atrophic Vaginitis**, but this candidate is supported by **zero clinical trials** and **zero publications**, and the model's own rationale flags it as a likely false positive driven by knowledge-graph term proximity ("vaginitis") rather than genuine pharmacology.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented in the regulatory dataset (no license records); drug class is nitroimidazole antiprotozoal/antibacterial |
| Predicted New Indication | Postmenopausal Atrophic Vaginitis |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for tinidazole was not available in this evidence pack (flagged as a High-severity data gap). Based on the mechanistic notes embedded elsewhere in this evidence pack, tinidazole is understood to be a 5-nitroimidazole drug whose activity is directed against protozoa (*Trichomonas vaginalis*, *Giardia*, *Entamoeba histolytica*) and anaerobic bacteria — an infection-clearance mechanism, not a hormonal or trophic one.

Postmenopausal atrophic vaginitis, by contrast, is caused by declining estrogen levels after menopause, leading to thinning and dryness of vaginal epithelium. It is not an infectious condition, and there is no established pharmacological pathway by which an antiprotozoal/antibacterial agent would address estrogen-deficiency-driven tissue atrophy.

The evidence pack's own repurposing rationale explicitly states this: the high TxGNN score is most plausibly explained by semantic clustering around the shared term "vaginitis" in the knowledge graph, rather than any genuine biological link. No clinical trials or literature support this association. **This prediction should be treated as a likely false positive rather than a genuine repurposing signal.**

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## India Market Information

Tinidazole currently has no registration records in the provided regulatory dataset (0 licenses, market status: Not marketed). No product/license information is available to summarize.

---

## Safety Considerations

**Drug Interactions**: A total of **161 drug-drug interactions** were identified (source: DDInter), all classified as Moderate severity. Representative interacting agents include:
- Ethanol, Amiodarone, Atorvastatin, Levodopa
- Oral contraceptive components (Ethinylestradiol, Estradiol)
- Multiple oncology agents (Paclitaxel, Cabazitaxel, Capecitabine, Bortezomib, Brentuximab vedotin, Trastuzumab emtansine, Brigatinib)
- Biologics/immunomodulators (Adalimumab, Auranofin)

No product-specific warnings or contraindications were available in this dataset — please refer to the official package insert for full safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (postmenopausal atrophic vaginitis) has no supporting clinical trials or literature, and the model's own mechanistic analysis identifies it as a probable knowledge-graph artifact rather than a biologically plausible repurposing candidate. Several other top-10 predictions (e.g., vulvar neoplasm, breast fibrocystic disease) share this same pattern and are similarly unsupported.

**To proceed, the following is needed:**
- If this candidate is to be pursued further, in vitro or mechanistic studies establishing any plausible pathway between nitroimidazole pharmacology and vaginal epithelial atrophy would be required — none currently exist.
- Regulatory label data (TFDA/CDSCO warnings and contraindications) to complete a baseline safety assessment (currently blocking S1 review).
- MOA confirmation from DrugBank or equivalent source.
- **Note for portfolio prioritization**: within this same evidence pack, the rank-5 candidate (AIDS) has at least indirect clinical trial and literature support (L4, one Phase NA trial, ~17 publications on trichomoniasis/amoebiasis management in HIV-positive populations), though the mechanistic link there is also indirect (treatment of co-infections rather than direct antiviral activity). If further investment in this drug is desired, that candidate — not the current top-ranked one — would be the more defensible starting point for a Research Question-stage inquiry.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

